An Update on Emerging Prostate Cancer Treatment Research

Published on

Topics include: Treatments

What’s the latest in prostate cancer treatment news? How is the treatment landscape changing? Patient Power founder Andrew Schorr is joined by leading expert Dr. Maha Hussain, from Robert H. Lurie Comprehensive Cancer Center of Northwestern University, to discuss recent developments in clinical trial research and early indications of the promise of PARP inhibitors for prostate cancer. Watch now to find out more.

This is a Patient Empowerment Network program produced by Patient Power in partnership with Robert H. Lurie Comprehensive Cancer Center of Northwestern University. We thank Astellas, Clovis Oncology and Pfizer for their support.

View more programs featuring and

Produced in association with and

Transcript

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Andrew Schorr:                     

Okay, and just to be clear, we've gone through the range of approved therapies, is there anything that has been changing the landscape of late?

Dr. Hussain:               

Well, actually, this is a perfect question in terms of timing because, just recently, there was the European Society of Medical Oncology meeting, ESMO, and there's some very interesting information emerging from large clinical trials that were conducted in Europe demonstrating the potential value for adding radiation to the prostate area in men who have metastatic disease that is responsive to hormone treatment, but do not have a lot of cancer in their bone or lymph nodes, where, in fact, radiating the prostate is leading to a prolongation in terms of overall survival, life prolongation.   

I would encourage patients who might have just started hormone treatment for metastatic disease to discuss with their doctors whether they would be appropriate candidates for this type of approach, and certainly, there is a lot of research going on to better understand the biology of prostate cancer and how the cancer escapes the effect of the treatment to try to come up with better treatments to attack it. One of those, I guess, treatments are the PARP inhibitors.

Andrew Schorr:                     

All right. Let's talk about that. We're producing this program just days after the European Society of Medical Oncology meeting has happened in Munich Germany, and so news comes out about different approaches. PARP inhibitors that you just mentioned had promise, I believe, in ovarian cancer and now they think in breast cancer, so do they have a role in prostate cancer, Dr. Hussain?

Dr. Hussain:               

Well, I think my gut feeling is yes. PARP inhibitors have had a track record in ovarian and in breast cancer, and there are several FDA approvals in that regard. We began to discover that there are subgroups of men with prostate cancer who are potential candidates for PARP inhibitors, therapy, and literally, I, just about two days from now, will be giving a special lecture at the Prostate Cancer Foundation and have a table of all the PARP inhibitor trials that are going on in the US or in other parts of the world, and it's an amazing list of clinical trials.

Several of these trials are what I would consider registrational trials, and several of them have either approved or are undergoing approval. It'll be interesting to see, at the end of the day, the results because that's really what's gonna prove the principle, but the early indication would suggest that it is quite likely that prostate cancer will be one of those diseases that will benefit from PARP inhibition.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Related Programs

When Do Emerging Prostate Cancer Therapies Become Standard of Care?

Prostate cancer experts Dr. Celestia Higano and Dr. Tomasz Beer share how patients can connect with the latest research developments and emerging therapies, and when to expect the standard of care to change.

Published:

Precision Medicine for Prostate Cancer: Treatment News Announced at ASCO 2018

What can genetic testing reveal about your prostate cancer? Is there a link between breast and prostate cancer mutations? Find out now from noted expert Dr. Heather Cheng on location at ASCO 2018.

Published:

The Role of Testosterone in Prostate Cancer Disease Behavior and Course of Treatment

Prostate cancer experts Dr. Maha Hussain and Brenda Martone discuss the testosterone link to prostate cancer, how hormone therapy works and medications to avoid. Watch now to hear their expert knowledge.

Published:

Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on March 5, 2019